We are very proud to have been the lead recruiter to the IBIS-II breast cancer prevention trial. As the leading recruiter in the world, our ladies have made a real difference and preliminary results indicate that the drug under trial, anastrozole, can reduce the risk of developing breast cancer by up to 50% in those at high risk.
Other studies currently in follow up:
- MA-32 – A study looking to see if metformin decreases the risk of recurrence.
- SOLE – When ladies had reached 5 years post-surgery they were randomised to take letrozole for a further 5 years either continuously or intermittently.